Evidence map›Paper›PMID 25392588›Full record

ArticleAfrican journal of traditional, complementary, and alternative medicines : AJTCAM2014

Effects of Ciji Hua'ai Baosheng granule formula (CHBGF) on life time, pathology, peripheral blood cells of tumor chemotherapy model mouse with H22 hepatoma carcinoma cells.

Shengyan Xi, Rongjian Hong, Jingru Huang, Dawei Lu, Linchao Qian, Pengcheng Li, Lei Wen, Yanhui Wang

Open access · diamondAbstract read
In one paragraph

Article in African journal of traditional, complementary, and alternative medicines : AJTCAM, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Using Traditional Chinese Medicine to Treat Hepatocellular Carcinoma by Targeting Tumor Immunity.Evidence-based complementary and alternative medicine : eCAM · 2020
    Review
  5. Article
  6. Review
  7. Article
  8. Preclinical Models for Investigation of Herbal Medicines in Liver Diseases: Update and Perspective.Evidence-based complementary and alternative medicine : eCAM · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Shengyan XiDepartment of Traditional Chinese Medicine, Medical College of Xiamen University; Cancer Research Center of Xiamen University, Xiamen 361102, China.
Rongjian HongShanghai Medical College, Fudan University, Shanghai 200032, China.
Jingru HuangLaboratory Center, Medical College of Xiamen University, Xiamen 361102, China.
Dawei LuDepartment of Traditional Chinese Medicine, Medical College of Xiamen University; Cancer Research Center of Xiamen University, Xiamen 361102, China.
Linchao QianDepartment of Traditional Chinese Medicine, Medical College of Xiamen University; Cancer Research Center of Xiamen University, Xiamen 361102, China.
Pengcheng LiDepartment of Traditional Chinese Medicine, Medical College of Xiamen University; Cancer Research Center of Xiamen University, Xiamen 361102, China.
Lei WenDepartment of Traditional Chinese Medicine, Medical College of Xiamen University; Cancer Research Center of Xiamen University, Xiamen 361102, China.
Yanhui WangDepartment of Traditional Chinese Medicine, Medical College of Xiamen University; Cancer Research Center of Xiamen University, Xiamen 361102, China.
Xiamen University · CNFudan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCiji Hua'ai Baosheng Granule Formula (CHBGF) is a traditional Chinese empirical formula that can help the tumor patients who have received chemotherapy antagonize the toxin and side-effects so as to improve and prolong the life. This study is to evaluate the effects of CHBGF on improving life quality in terms of survival time, pathology of tumor tissue and ameliorating peripheral blood cells in mouse chemotherapy model with subcutaneous transplanted tumor or ascitic tumor of H22 hepatoma carcinoma cells at an overall level. MATERIALS AND

methods71 mice among the 92 Kunming mice were injected subcutaneously into the right anterior armpit with H22 hepatoma carcinoma cells, after 7 days, which had formed tumors and were used peritoneal injection of Cytoxan (CTX) (200mg/kg) to establish the mouse chemotherapy model with transplanted tumor, and then which were commensurately divided into 8 groups by random digits table. 21 mice were injected into peritoneal cavity to use CTX and the same method to establish the model. The groups for evaluating the effects on the survival time were the model, CHBGF and positive control group respectively with 7 mice in each group. The groups for evaluating the effects on anti-cancer were the model group, three treatment groups and positive control group with 10 mice in each group. The survival-time-observing groups were given intragastric administration of normal saline, CHBGF (64g/kg) once a day, and peritoneal injection of 5-Fluorouracil (25mg/kg) once every other day respectively. The survival time of each group was observed. The five anti-cancer-observing groups were given intragastric administration of normal saline, CHBGF (64g/kg, 32g/kg and 16g/kg) once a day, and peritoneal injection of 5-Fluorouracil (25mg/kg) once every other day respectively. After treatment for 21 days, the transplanted tumors were peeled off. Blood was collected through pricking eyeball and analyzed by hematology analyzer. And postchemotherapy transplanted tumor inhibition ratios were calculated. Pathological changes of tumor tissues and blood smears were observed with light microscope.

resultsThe life prolonging rate of CHBGF (64g/kg) group with transplanted tumor is 20.14%, and their survival time was longer than that of the 5-Fluorouracil group (P<0.05). Life prolonging rate of CHBGF (64g/kg) group with ascitic tumor is 64.15%, the survival time was longer than that of the model group (P<0.01) and the 5-Fluorouracil group (P<0.05). The growth of the transplanted tumor in model group was faster than that in CHBGF (64g/kg) group and 5-Fluorouracil group (P<0.05). The tumor average weight of the positive drug and the CHBGF (64g/kg, 32g/kg) groups was lighter than that of the model group (P<0.05 or P<0.01). The inhibition ratios of CHBGF (64g/kg, 32g/kg and 16g/kg) groups are 31.15%, 21.31%, and 13.11% respectively. Under light microscope, in the positive drug and three CHBGF groups the pathological deteriorated severity of tumor tissue observed was milder than that in the model group, the distribution of WBC in CHBGF groups was more obvious than that of the model and 5-Fluorouracil groups. The WBC and PLT decrease in CHBGF (64g/kg, 32g/kg and 16g/kg) groups is less than the model and the 5-Fluorouracil group (P<0.05 or P<0.01), the number of RBC and HGB just in the CHBGF (64g/kg) group was more than that of the model group or the 5-Fluorouracil group (P<0.05).

conclusionCiji Hua'ai Baosheng Granule Formula can prolong the survival time of the mice chemotherapy model of both subcutaneous transplanted tumor and ascitic tumor of H22 hepatoma carcinoma cells, has some determinate inhibitory effects on the growth of subcutaneous transplanted tumor chemo-treated, and has the therapeutic effect on antagonizing decrease of WBC and PLT caused by chemotherapy.

Indexed as

PhytotherapyAnimalsAntineoplastic Agents, PhytogenicBlood CellsBlood PlateletsCarcinoma, HepatocellularDisease Models, AnimalDrugs, Chinese HerbalHumansLeukocytesLiverLiver NeoplasmsMiceMice, Inbred StrainsNeoplasm TransplantationAntineoplastic Agents, PhytogenicDrugs, Chinese Herbalascitic tumorCiji Hua'ai Baosheng Granule Formula (CHBGF)H22 hepatoma carcinoma cellpathologyperipheral blood cellsurvival timetransplanted tumortumor chemotherapy model

Identifiers

PMID25392588
PMCPMC4202404
OpenAlexW2056023747

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.